Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. class action asserts India’s Ranbaxy manipulated FDA rules

A Ranbaxy office building is pictured in the northern Indian city of Mohali May 14, 2013. Reuters/Ajay Verma Indian generic drugmaker Ranbaxy Laboratories Ltd has been sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market. […]

Read More »

Ogilvy CommonHealth Worldwide’s Jill Lesiak Honored as HBA Rising Star

PARSIPPANY, NJ–(Marketwired – May 14, 2015) – Ogilvy CommonHealth Worldwide (, the health behavior change experts of Ogilvy & Mather (, and a WPP company (NASDAQ: WPPGY) (, today announced Jill Lesiak, vice president, creative director at the network’s Parsippany-based agency, Ogilvy CommonHealth, was named an industry Rising Star by the Healthcare Businesswomen’s Association (HBA) […]

Read More »

Takeda Reports Top Line Results in Line With Guidance, With Underlying Growth of +2.8% EPS Affected by One-time Charges in FY2014 Back to Profitable Growth from FY2015 Onward

OSAKA, Japan, May 15, 2015 /PRNewswire/ — Operational guidance met  Growth supported by innovative new products  Regional top line performance on track  Efficiency gains above target  Exceptional items impacting bottom line  Guidance: Back to profitable growth from FY2015  180 yen dividend per share for FY2015 and strives to at least maintain the 180 yen annual dividend per […]

Read More »

Investing in Cannabis Testing Labs and Expansion of Marijuana News Focus of DigiPath, Inc., 10-Q

LAS VEGAS, May 13, 2015 /PRNewswire/ — DigiPath, Inc. (OTCBB and OTCQB: DIGP), the independent cannabis testing, media, digital pathology, and education firm, announced the filing of its quarterly report on Form 10-Q for its second fiscal quarter ended March 31, 2015, with the Securities and Exchange Commission. “DigiPath ended the quarter with $3.9 million of […]

Read More »

Puma Biotechnology Founder Auerbach Loses $250 Million On Cancer Drug Data

On Wednesday afternoon, Forbes estimated Puma Biotechnology Founder, Chairman, and Chief Executive Alan Auerbach’s net worth at $1.19 billion. Then long-awaited details on a positive clinical trial of Puma’s breast cancer drug, neratinib, were released. Puma shares, which had spiked a year ago and made Auerbach a billionaire when it was first announced the study […]

Read More »

Bolstering Cancer Strategy, German Biotech BioNTech and Eli Lilly Ink $360 Million Research Deal

Mainz, Germany-based BioNTech announced yesterday that it had signed a research collaboration agreement with Indianapolis-based Eli Lilly and Company (LLY). The deal, which starts with a $30 million signing fee, will focus on discovering novel cancer immunotherapies. In addition, Lilly is investing another $30 million equity investment in Cell & Gene Therapies GmbH, a subsidiary […]

Read More »

Baxter International Puts Down $900 Million to Beef Up Cancer Products for Spinoff

Deerfield, Ill.-based Baxter International (BAX) said Tuesday it would buy a promising leukemia treatment, Oncaspar, from Italian company Sigma-Tau Finanziaria S.p.A. for $900 million, as it bolsters its oncology pipeline in an increasingly lucrative and competitive field. Baxter estimated oncology alone could bring in $10 billion once its pipeline is established, with Oncaspar already raking […]

Read More »

GSK’s Curious Oncology Research Position – A Recipe For Failure?

In April of 2014, GSK and Novartis announced a swap of assets, with GSK acquiring the Novartis global Vaccines business (excluding influenza vaccines) and Novartis gaining the GSK Oncology business. In addition, the two companies announced the creation of a new Consumer Healthcare joint venture. At the time, GSK’s CEO Sir Andrew Witty said that: […]

Read More »

Endo Pharmaceuticals Shells Out $130 Million for Nearly 70 Pipeline Programs From Aspen Pharmacare Holdings

DUBLIN — Endo International (ENDP) has continued its trend of expanding its portfolio through acquisitions, announcing a $130 million deal to acquire a large portfolio of anti-pain anti-infectives, cardiovascular and other therapeutics areas from Aspen Pharmacare Holdings, the company said this morning. The deal includes products that are currently on the market, as well as […]

Read More »

Defenders Unite Against Cyber Threats In Healthcare

The screenshot above is courtesy of Norse ‒ a cyber intelligence company that uses their global sensor network to track cyber threats around the world ‒ in real time (online here).  Warning ‒ this global view can be a tad mesmerizing if you haven’t seen it. There’s no audio, but it’s easy to imagine a […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom